Related references
Note: Only part of the references are listed.Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation
Kan Li et al.
CHEMISTRY & BIODIVERSITY (2019)
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow
Xavier Fradera et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
Yuichi Ando et al.
CANCER SCIENCE (2019)
Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters
Conrad Stork et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)
Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
Jingyu Zhu et al.
RSC ADVANCES (2019)
Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET
Pankaj Kumar Singh et al.
BIOORGANIC CHEMISTRY (2018)
Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration
Ahmed Y. Ali et al.
LEUKEMIA (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
William J. Scott et al.
CHEMMEDCHEM (2016)
A Novel Method to Detect Functional microRNA Regulatory Modules by Bicliques Merging
Cheng Liang et al.
IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS (2016)
Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power
Zhe Wang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2016)
Badapple: promiscuity patterns from noisy evidence
Jeremy J. Yang et al.
JOURNAL OF CHEMINFORMATICS (2016)
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies
Jingyu Zhu et al.
DRUG DISCOVERY TODAY (2015)
Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
Manman Wei et al.
MEDICINAL RESEARCH REVIEWS (2015)
Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
Timothy D. Cushing et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ
Philip N. Collier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
Jingyu Zhu et al.
ONCOTARGET (2015)
Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
J. Zhu et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis
Mutasem O. Taha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility
Sheng Tian et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo
Juan Tang et al.
ONCOTARGET (2014)
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
Hengmiao Cheng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors
Kathryn Bell et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
Jorge J. Castillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease
Mhairi J. Maxwell et al.
JOURNAL OF AUTOIMMUNITY (2012)
Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors
James W. Leahy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors
Felix Gonzalez-Lopez de Turiso et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases
Timothy D. Cushing et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511
Mark H. Norman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Steven T. Staben et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism
Xuxiao Zhang et al.
MOLECULAR CELL (2011)
Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: a Prototype for New Anti-inflammatory Drugs
Olusegun Williams et al.
CHEMISTRY & BIOLOGY (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
C. Garcia-Echeverria et al.
ONCOGENE (2008)
Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease
Kazuhiro Ito et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
PI3Kγ inhibition:: towards an 'aspirin of the 21st century'?
Thomas Rueckle et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Signalling through class I PI3Ks in mammalian cells
P. T. Hawkins et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ
Vincent Pomel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus
DF Barber et al.
NATURE MEDICINE (2005)
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
M Camps et al.
NATURE MEDICINE (2005)
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
K Hamada et al.
GENES & DEVELOPMENT (2005)
Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides
GA Kaminski et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2001)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
